Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer.
Background: The American Joint Committee on Cancer staging and other prognostic tools fail to account for stage-independent variability in outcome. We developed a prognostic classifier adding Immunoscore to clinicopathological and molecular features in patients with stage III colon cancer.
Methods: Patient (n = 559) data from the FOLFOX arm of adjuvant trial NCCTG N0147 were used to construct Cox models for predicting disease-free survival (DFS). Variables included age, sex, T stage, positive lymph nodes (+LNs), N stage, performance status, histologic grade, sidedness,
Results: Poorer DFS was found for tumors that were T4 vs T3 (hazard ratio [HR] = 1.76, 95% confidence interval [CI] = 1.19 to 2.60;
Conclusions: The Immunoscore can enhance the accuracy of survival prediction among patients with stage III colon cancer.
Published In/Presented At
Sinicrope, F. A., Shi, Q., Hermitte, F., Zemla, T. J., Mlecnik, B., Benson, A. B., Gill, S., Goldberg, R. M., Kahlenberg, M. S., Nair, S. G., Shields, A. F., Smyrk, T. C., Galon, J., & Alberts, S. R. (2020). Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI cancer spectrum, 4(3), pkaa023. https://doi.org/10.1093/jncics/pkaa023
Medicine and Health Sciences | Oncology
Peer Reviewed for front end display
Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty